Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
|
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [22] FINERENONE ADDED TO TREATMENT GUIDELINES FOR TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2023, 123 (05) : 23 - 23
  • [23] Consensus Document on treatment of type 2 diabetes in patients with chronic kidney disease
    Gomez-Huelgas, Ricardo
    Martinez-Castelao, Alberto
    Artola, Sara
    Gorriz, Jose L.
    Menendez, Edelmiro
    NEFROLOGIA, 2014, 34 (01): : 34 - 45
  • [24] CYSTATIN C IN THE DIAGNOSIS OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    Yarkova, N. A.
    Borovkov, N. N.
    Zanozina, O. V.
    Nosov, V. P.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2013, 5 (04) : 89 - 92
  • [25] Semaglutide for Chronic Kidney Disease in Type 2 Diabetes
    Passos, Rogerio da Hora
    Narciso, Roberto Camargo
    da Silva, Arnaldo Alves
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (18): : 1757 - 1757
  • [26] Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007)
    Assogba, G. F. A.
    Couchoud, C.
    Roudier, C.
    Pornet, C.
    Fosse, S.
    Romon, I.
    Druet, C.
    Stengel, B.
    Fagot-Campagna, A.
    DIABETES & METABOLISM, 2012, 38 (06) : 558 - 566
  • [27] Treatment options for chronic kidney disease in type 1 diabetes
    Numberger, Markus
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (02) : 110 - 110
  • [28] Screening and Management Recommendations for Type 2 Diabetes in Women With Breast Cancer
    Scott, Laura
    Truong, Lan-Linh
    Houlden, Robyn L.
    Wijeratne, Don Thiwanka
    CANADIAN JOURNAL OF DIABETES, 2024, 48 (01) : 66 - 72
  • [29] Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
    Ortiz, Alberto
    Arroyo, Roberto Alcazar
    Escribano, Pedro Pablo Casado
    Fernandez-Fernandez, Beatriz
    Deben, Francisco Martinez
    Mediavilla, Juan Diego
    Michan-Dona, Alfredo
    Soler, Maria Jose
    Gorriz, Jose Luis
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (06) : 519 - 531
  • [30] Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
    Scott, David
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 359 - 363